Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from Genmab ( (GMAB) ) is now available.
On March 31, 2025, Genmab A/S announced the initiation of a share buy-back program to repurchase up to 2.2 million shares, aiming to reduce capital and fulfill commitments under their Restricted Stock Unit program. The transactions executed between March 26 and March 28, 2025, resulted in Genmab holding 2,771,544 shares as treasury shares, representing 4.19% of the total share capital. This move is expected to impact Genmab’s financial structure and market positioning positively, aligning with the company’s strategic goals under the Safe Harbour Regulation.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. The company has been pioneering next-generation antibody technology platforms for over 25 years, aiming to transform the lives of patients with cancer and other serious diseases through its proprietary pipeline, including bispecific T-cell engagers and antibody-drug conjugates.
YTD Price Performance: -5.24%
Average Trading Volume: 1,497,710
Technical Sentiment Signal: Buy
Current Market Cap: $12.58B
For a thorough assessment of GMAB stock, go to TipRanks’ Stock Analysis page.